GUT-4D · From Stool to Solutions: Diagnose, Decode, Disruptors, and Deliver Interventions for the Human Gut Microbiota in Neurodegenerative Diseases.
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-10-01 → 2030-09-30
- Финансиране от ЕС
- 1 568 130 €
- Участници
- 13
- Схема
- HORIZON-TMA-MSCA-SE
Линиите свързват координатора с партньорите.
Накратко на български
Чревните бактерии и тяхната връзка с невродегенеративни заболявания, като болестите на Алцхаймер и Паркинсон, се анализират чрез проби от изпражнения. Това помага за по-точна диагностика и разработване на методи за подобряване на здравето на организма.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
GUT-4D tackles a pivotal frontier in biomedicine: leveraging the gut microbiome to transform the diagnosis, mechanistic understanding, and treatment of neurodegenerative diseases (NDDs) including Parkinson’s, Alzheimer’s, frontotemporal dementia, and amyotrophic lateral sclerosis. The project unites four interconnected research pillars, stool-based diagnostics, gut–disease mechanistic links, dysbiosis drivers, and microbiota-improving interventions, within a rigorously standardized clinical framework for sample and data management. First, GUT-4D will deliver clinically translatable, stool-based biomarker panels by integrating metagenomics, metaproteomics, metabolomics, and host markers with multi-class machine-learning models, overcoming the limitations of single-disease, binary classifiers and advancing omics diagnostics toward validated, assay-ready tools. Second, it will dissect causal gut–brain and gut–immune pathways by combining deeply phenotyped patient cohorts with ex vivo and in vitro mechanistic experiments, mapping microbial metabolites and host proteins, to reveal disease-specific triggers. Third, the project pioneers an exposome–microbiome pipeline that detects exogenous compounds and microbial products directly in fecal samples and applies Exposome-Wide Association analyses, followed by rapid ex vivo functional testing and targeted cellular assays, to build a Modifiable Driver Atlas of actionable dysbiosis factors. Finally, GUT-4D translates insights into therapeutic strategies with pre/pro/synbiotics, postbiotics, and other ecosystem “repair” approaches validated on adaptive ex vivo platforms. By integrating microbiology, clinical medicine, data science, and environmental health, GUT-4D provides a four-dimensional, bench-to-bedside program poised to shift NDD care from correlative observations to predictive, mechanism-guided diagnostics and interventions, strengthening Europe’s capacity for next-generation, microbiome-enabled healthcare.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO · VercelliКоординаторИталия
- COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · ParisФранция
- CONSIGLIO NAZIONALE DELLE RICERCHE · RomaИталия
- EREVNITIKO KENTRO VIOIATRIKON EPISTIMON ALEXANDROS FLEMINGK · Vari-AthensГърция
- GEORGETOWN UNIVERSITY NON PROFIT CORPORATION · Washington DcСъединени щати
- INSPIRE SCIENCE SRL · JUDET CLUJРумъния
- KING'S COLLEGE LONDON · LondonОбединеното кралство
- NOVAMECHANICS LIMITED · NicosiaКипър
- Nova Southeastern University · Fort LauderdaleСъединени щати
- POLO D'INNOVAZIONE DI GENOMICA, GENETICA E BIOLOGIA SRL · SienaИталия
- PRINSUS I.K.E. TECHNOVLASTOS · ZOGRAFOU, ATHENSГърция
- REGION HOVEDSTADEN · HillerodДания
- UNIVERSITATEA DE STIINTE AGRICOLE SI MEDICINA VETERINARA CLUJ NAPOCA · Cluj NapocaРумъния
Връзки
Данни: CORDIS, © Европейски съюз
